Abstract 2116
Background
Epithelial-to-mesenchymal transition (EMT) plays essential roles in non-small cell lung cancer (NSCLC) progression and was related to TWIST1 reactivation. Among regulators of EMT, microRNAs are extensively studied. This work aimed at identifying microRNAs that might be important regulators of TWIST1 and EMT in NSCLC.
Methods
We performed miRSeq in a series of EGFR-mutated lung adenocarcinomas (n = 24, series A) and identified a set of miRNAs (n = 12) associated to TWIST1 reactivation. These miRNAs and additional EMT-related miRNAs selected from the literature and from TCGA public data were reanalysed by Fluidigm® technology on the same series. Two miRNAs were significantly associated with TWIST1 reactivation. We then quantified these two miRNAs in a series of 176 consecutive operated NSCLC (series B), in addition to E-cadherin, Jup, N-cadherin, Zeb1, Snai1, Twist1, Vimentin, TCF3 and CD44 using qPCR. Results were validated using TCGA public data.
Results
MiR-200a-3p and miR-429 were significantly associated with TWIST1 reactivation (p = 0.018) in series A, not confirmed by the 16 EGFR-mutated lung adenocarcinomas of series B, but by TCGA analysis (p = 0.03). In series B, miR-200a-3p and miR-429 expression levels were highly correlated (p < 0.001) together and associated to Twist1 up-regulation (p = 0.02 and p = 0.07, respectively), EMT (p = 0.003) and stem cell features (p < 0.05). Low miR-200a-3p and miR-429 expression levels were significantly associated with overall survival in multivariate analyses (Cox; p = 0.008 and p = 0.01, respectively), thus identified as independent prognostic factors. TCGA overall survival multivariate analyses confirmed this finding (p < 0.02).
Conclusions
This study provides new insights on the clinical impact of miR-200 family members down-regulation in localized NSCLC. EMT targeting should be considered as a therapeutic option for a subset of NSCLC patients.
Clinical trial identification
trial protocol number under request
Legal entity responsible for the study
Assistance Publique des Hôpitaux de Paris.
Funding
Site de la Recherche Intégrée sur le Cancer (SIRIC) Cancer Research for Personalized Medicine (Carpem).
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract